<i>NOTCH1</i> Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial
Our data provide novel insights for anti-PD-1 treatment selection using <i>NOTCH1</i> mutations and may provide a rationale for combination therapy in ESCC.
Authors
- Ningning Ding (ORCID: https://orcid.org/0000-0002-3937-7302)
- Yanni Wang (ORCID: https://orcid.org/0000-0002-3423-8434)
- Yang Shi (ORCID: https://orcid.org/0000-0002-7185-0972)
- Wenting Du (ORCID: https://orcid.org/0000-0001-6765-0129)
- Hiroki Hara (ORCID: https://orcid.org/0000-0003-3881-9815)
- Zuoxing Niu (ORCID: https://orcid.org/0000-0001-6709-7298)
- Jun Wu (ORCID: https://orcid.org/0000-0003-1834-9596)
- Jingwen Shi (ORCID: https://orcid.org/0000-0002-4802-0727)
- Lin Shen (ORCID: https://orcid.org/0000-0002-8798-4756)
- Yongqian Shu (ORCID: https://orcid.org/0000-0003-2103-0877)
- Chih‐Hung Hsu (ORCID: https://orcid.org/0000-0003-0495-973X)
- Eric Van Cutsem (ORCID: https://orcid.org/0000-0002-6372-1230)
- Yun Zhang (ORCID: https://orcid.org/0000-0003-1614-1943)
- Zhang Zhang (ORCID: https://orcid.org/0000-0001-6603-5060)
- Xi Jiao (ORCID: https://orcid.org/0000-0002-5588-5657)
- Zhirong Shen
- Malcolm V. Brock
Institutions
- Johns Hopkins University (US)
- Peking University (CN)
- Johns Hopkins Medicine (US)
- Peking University Cancer Hospital (CN)
- BeiGene (China) (CN)
- Shandong Tumor Hospital (CN)
- The First People's Hospital of Changzhou (CN)
- Saitama Cancer Center (JP)
- National Taiwan University Hospital (TW)
- Jiangsu Province Hospital (CN)
- Shandong First Medical University (CN)
- Nanjing Medical University (CN)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1200/jco-24-01818
- Citations
- 10
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 20.06